diagnostic

Braid.Health to Showcase Universal Access to Accelerated Diagnostic Image Interpretation at RSNA 2019

“Everyone deserves the best care in an accelerated manner regardless of where they live, how much money they have, or what they know, and that is why we created Braid.Health.”

SAN FRANCISCO (PRWEB) December 02, 2019
Braid.Health, developer of advanced artificial intelligence (AI) technology supporting radiologists and healthcare providers globally announced that it will be showcasing Braid at the Radiological Society of North America (RSNA) 2019, Chicago, IL, Booth #7962 North Hall. Braid is designed to close the gap in care by providing patients with accelerated diagnostic interpretation and providing radiologists and healthcare professionals with innovative AI technology that is pushing the boundaries of conventional care.
Braid.Health understands diagnostic image interpretation can be critical for patients at any time; anywhere.
“We have developed Braid.Health, an AI powered software solution that connects healthcare professionals with radiologists allowing for near instantaneous interpretation,” said Alessandro Sabatelli, Co-Founder and Chief Product Officer of Braid.Health. “These connections are needed most at the edges of the healthcare system, not only in rural areas, but also in clinics within major metropolitan areas. As is often the case, you only get one chance to diagnose early and this requires expert care.”
Braid.Health welcomes radiologists and potential integration partners to visit with them to engage in discussion and discover how together we can provide universal access to medical expertise.
“Everyone deserves the best care in an accelerated manner regardless of where they live, how much money they have, or what they know, and that is why we created Braid.Health,” said Sabatelli.
In a recent study conducted by the Journal of the American College of Radiology (ACR) burnout amongst radiologists continues to be a prominent problem with 55% of practice leaders responding that it is very significant with 22% reporting significant.
“Having innovative technology that can be supportive to radiologist with first reads and/or second reads powered through AI can assist with the burnout factors; allowing for a better quality of life for radiologists and providing patients with accelerated access to diagnosis,” said Sabatelli.
Braid.Health looks forward to engaging with you at RSNA 2019 to experience Braid and the future of connected healthcare with our end-to-end radiology workflow. We believe the best possible care is made possible through Radiologists and AI partnering together.
Braid solutions are investigational devices in the US and limited by US Federal Law to investigational use.
To learn more please visit Braid.Health at RSNA 2019, #7962 North Hall and visit us a http://www.braid.health.
About Braid
Braid.Health is a digital health innovation company founded in 2018 by Kevin Quennesson and Alessandro Sabatelli, developers behind the Apple Watch, iPhone and Siri. The company is backed by Lux Capital and other prominent investors including former Twitter CEO and COO Dick Costolo and Adam Bain. Braid.Health has built the premier AI-communications platform for radiology and the healthcare industry. Braid.Health is collaborating with major hospitals, industry veterans, and award-winning physicians to re-invent the imaging experience with AI at its core. With its products, Braid.Health seeks to enhance diagnosis accuracy and unlock the next generation of augmented radiology. The company is headquartered in San Francisco.

Share article on social media or email:

The Center for Diagnostic Imaging Discusses How Breast MRIs Can Help Prevent Breast Cancer

Press Release – updated: Nov 27, 2019 16:56 EST

MIAMI, November 27, 2019 (Newswire.com) – The Center for Diagnostic Imaging of Miami offers unparalleled breast MRI procedures for those seeking preventative breast care. Women who have a 20% lifetime risk of getting breast cancer are sometimes recommended to go for a breast MRI along with a screening mammogram. 
A Breast MRI should not be used in place of a breast biopsy to differentiate between benign and malignant tumors. MRIs are able to detect tumors in dense breast tissue, but having dense breasts does not necessitate a breast MRI scan. Breast MRIs are similar to diagnostic mammograms in that they require specially designed equipment. Instead of radiation, an MRI uses a magnetic field to generate cross-sectional pictures of the body. An MRI takes pictures of the breasts from different angles on the side, and in front and above the head. Thus, it is better at getting difficult images that other tests may not get as accurately. 
​How to Prepare for the Test
First, a breast MRI needs approval by a person’s insurance company, as the procedure can be very expensive. Many private insurance companies pay for mammogram tests, so they will pay for an MRI exam if a woman has a high risk of breast cancer. 
Patients must follow certain instructions before undergoing a scan. Patients do not have to follow a special diet before the examination, however, there are certain precautions patients may wish to follow, such as taking a sedative if they are claustrophobic. Some MRI centers are conducted with more personal space, so people can feel more comfortable. Other metal devices should be removed prior to the beginning of the exam. 
About CDI: The Center for Diagnostic Imaging is one of Miami’s leading diagnostic facilities. With over 20 years of experience, CDI has successfully provided the best services and results in digital imaging and patient care.
The center is owned and operated by a team of board-certified physicians and staff determined to be South Florida’s premier imaging series. CDI is dedicated to serving the healthcare needs of the community through the use of the most highly advanced technology and techniques currently available within the imaging industry. As a premier imaging center in Miami, CDI offers CT scans in Miami, mammograms in Miami, and MRIs in Miami Beach.
For more information on or to set up an appointment with The Center for Diagnostic Imaging, call 1-800-371-0002. 
Source: The Center for Diagnostic Imaging

The Center for Diagnostic Imaging Discusses How Breast MRIs Can Help Prevent Breast Cancer

Press Release – updated: Nov 27, 2019 16:56 EST

MIAMI, November 27, 2019 (Newswire.com) – The Center for Diagnostic Imaging of Miami offers unparalleled breast MRI procedures for those seeking preventative breast care. Women who have a 20% lifetime risk of getting breast cancer are sometimes recommended to go for a breast MRI along with a screening mammogram. 
A Breast MRI should not be used in place of a breast biopsy to differentiate between benign and malignant tumors. MRIs are able to detect tumors in dense breast tissue, but having dense breasts does not necessitate a breast MRI scan. Breast MRIs are similar to diagnostic mammograms in that they require specially designed equipment. Instead of radiation, an MRI uses a magnetic field to generate cross-sectional pictures of the body. An MRI takes pictures of the breasts from different angles on the side, and in front and above the head. Thus, it is better at getting difficult images that other tests may not get as accurately. 
​How to Prepare for the Test
First, a breast MRI needs approval by a person’s insurance company, as the procedure can be very expensive. Many private insurance companies pay for mammogram tests, so they will pay for an MRI exam if a woman has a high risk of breast cancer. 
Patients must follow certain instructions before undergoing a scan. Patients do not have to follow a special diet before the examination, however, there are certain precautions patients may wish to follow, such as taking a sedative if they are claustrophobic. Some MRI centers are conducted with more personal space, so people can feel more comfortable. Other metal devices should be removed prior to the beginning of the exam. 
About CDI: The Center for Diagnostic Imaging is one of Miami’s leading diagnostic facilities. With over 20 years of experience, CDI has successfully provided the best services and results in digital imaging and patient care.
The center is owned and operated by a team of board-certified physicians and staff determined to be South Florida’s premier imaging series. CDI is dedicated to serving the healthcare needs of the community through the use of the most highly advanced technology and techniques currently available within the imaging industry. As a premier imaging center in Miami, CDI offers CT scans in Miami, mammograms in Miami, and MRIs in Miami Beach.
For more information on or to set up an appointment with The Center for Diagnostic Imaging, call 1-800-371-0002. 
Source: The Center for Diagnostic Imaging

The Center for Diagnostic Imaging Discusses How Breast MRIs Can Help Prevent Breast Cancer

Press Release – updated: Nov 27, 2019 16:56 EST

MIAMI, November 27, 2019 (Newswire.com) – The Center for Diagnostic Imaging of Miami offers unparalleled breast MRI procedures for those seeking preventative breast care. Women who have a 20% lifetime risk of getting breast cancer are sometimes recommended to go for a breast MRI along with a screening mammogram. 
A Breast MRI should not be used in place of a breast biopsy to differentiate between benign and malignant tumors. MRIs are able to detect tumors in dense breast tissue, but having dense breasts does not necessitate a breast MRI scan. Breast MRIs are similar to diagnostic mammograms in that they require specially designed equipment. Instead of radiation, an MRI uses a magnetic field to generate cross-sectional pictures of the body. An MRI takes pictures of the breasts from different angles on the side, and in front and above the head. Thus, it is better at getting difficult images that other tests may not get as accurately. 
​How to Prepare for the Test
First, a breast MRI needs approval by a person’s insurance company, as the procedure can be very expensive. Many private insurance companies pay for mammogram tests, so they will pay for an MRI exam if a woman has a high risk of breast cancer. 
Patients must follow certain instructions before undergoing a scan. Patients do not have to follow a special diet before the examination, however, there are certain precautions patients may wish to follow, such as taking a sedative if they are claustrophobic. Some MRI centers are conducted with more personal space, so people can feel more comfortable. Other metal devices should be removed prior to the beginning of the exam. 
About CDI: The Center for Diagnostic Imaging is one of Miami’s leading diagnostic facilities. With over 20 years of experience, CDI has successfully provided the best services and results in digital imaging and patient care.
The center is owned and operated by a team of board-certified physicians and staff determined to be South Florida’s premier imaging series. CDI is dedicated to serving the healthcare needs of the community through the use of the most highly advanced technology and techniques currently available within the imaging industry. As a premier imaging center in Miami, CDI offers CT scans in Miami, mammograms in Miami, and MRIs in Miami Beach.
For more information on or to set up an appointment with The Center for Diagnostic Imaging, call 1-800-371-0002. 
Source: The Center for Diagnostic Imaging

For 2nd Year, PFI Advisors Announces Free Operational Diagnostic to RIAs Participating in its #GivingTuesday Campaign

#GivingTuesday is recognized as an international day of giving at the beginning of the holiday season; PFI Advisors will do its part by providing a free Operational Diagnostic to RIAs that donate $10,000 or more to the Children’s Hospital Los Angeles donation page of Layla Paige Sonnen(PRWeb November 12, 2019)Read the full story at https://www.prweb.com/releases/for_2nd_year_pfi_advisors_announces_free_operational_diagnostic_to_rias_participating_in_its_givingtuesday_campaign/prweb16707736.htm

Affinimark Receives Breakthrough Designation from FDA for Diagnostic in the Detection of Cerebral Spinal Fluid Leaks in Patients

GUILFORD, Conn. (PRWEB) October 25, 2019
Affinimark Technologies, Inc. ( Affinimark), a development-stage diagnostics company dedicated to improving timely diagnosis and treatment for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for its review of Affinimark’s proprietary Cerebral Spinal Fluid (CSF) Test Strip, a revolutionary diagnostic strip intended for real-time detection of cerebral spinal fluid leaks. FDA Breakthrough Designation expedites the Agency’s review of medical devices that can provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Affinimark’s CSF test works much like a pregnancy test, yielding a positive or negative result when suspected fluid is tested. The immediate feedback assists the clinician making a diagnosis and helps to determine if any intervention is necessary to address a CSF leak. CSF supports and bathes the brain and central nervous system. Leaks occur when a tear or hole forms in the dura, the membrane that surrounds the brain and spinal cord, allowing fluid to seep out, increasing the risk of infection.
“The FDA’s granting of Breakthrough Designation for our CSF Test Strip underscores the urgent need for a diagnostic tool that provides on-the-spot, immediate results upon suspicion of a CSF leak in patients,” said Ellie Tandler, President and Chief Executive Officer at Affinimark. “CSF leaks increase the risk of meningitis and other neurological complications, so timely diagnosis and urgent and effective repair of the defect are essential. We appreciate the review and decision by the FDA and plan to work closely with the Agency to commercialize our CSF Test Strip by early 2021.”
Among the benefits of FDA Breakthrough Designation are a commitment from the FDA for more rapid review timelines, ongoing discussion and submission review, and access to FDA senior management to develop a plan that is as least burdensome as possible and allows for some measure of flexibility and adjustment. The FDA’s decision was based on recognition of Affinimark’s CFS Test Strip as a timely diagnostic tool that can aid in the diagnosis of CSF leakages more quickly than other available in vitro diagnostic (IVD) devices with the same or similar intended use.
“Our device has completed proof-of-concept and prototyping. We are raising a Series C round of financing to fund the clinical trial and analytical bench testing of the strip over the next 18 months for a de novo 510(k) submission to the FDA by Q1 2021,” added Tandler.
Current technologies for detecting CSF fluid leaks, such as imaging and scans, are time-consuming, expensive and inconvenient for the patient. A beta-2 transferrin lab test can detect CSF; however, the test requires a relatively large volume sample (as compared with Affinimark’s test), can be cumbersome to run and can produce inaccurate results when blood is present in the sample. Its performance data have not been reviewed by the FDA.
About Affinimark Technologies, Inc.:Affinimark Technologies, Inc., is a privately held diagnostics company located in Guilford, CT. Its primary investors include CT Innovations and Launch Capital, as well as individual founders.

Share article on social media or email:

Neurolign Advances With the Acquisition of Eye Diagnostic Technology Company

Neurolign, the neurological diagnostic and pharmaceutical company advances its diagnostics with the acquisition of Neuro Kinetics Inc., a leader in non-invasive neurofunctional eye tracking diagnostic testing
TORONTO, October 10, 2019 (Newswire.com) – ​​​Neurolign Technologies Inc. (“Neurolign”) announced today the acquisition of Neuro Kinetics Inc. of Pittsburgh, Pennsylvania, a world leader in clinical eye-tracking and non-invasive neurofunctional diagnostic testing, delivering leading-edge neurofunctional assessments.  
Neurolign is a privately held diagnostic and pharmaceutical company focused on bringing superior diagnostic solutions and novel therapeutics for the diagnosis and treatment of neurological conditions to physicians and their patients. Neurolign’s founder is Eugene Melnyk, the creator of multiple healthcare companies, including Biovail Corporation (acquired by Bausch Health), and the current owner of the Ottawa Senators Hockey Club. Through this transaction, Neurolign will acquire the assets and operations of Neuro Kinetics, including customer relationships, all products, technologies, related intellectual property, fixed assets, and will assume certain liabilities.
“The acquisition of Neuro Kinetics accelerates Neurolign’s mission to research, develop and provide access to world-class diagnostics and targeted pharmaceutical therapeutics to improve the lives of patients suffering from neurological disorders, initially beginning with concussion,” said Eugene Melnyk, Neurolign Chairman and Chief Executive Officer. “After watching concussed athletes in sport, and its impact on these athletes and their families, there is a need to advance clinicians’ abilities to diagnose and determine when athletes can safely return to playing sports. We will address this through transforming not just diagnosis and treatment of concussion, but also for a wide array of neurological disorders affecting the global community.” 
“Traumatic Brain Injury, TBI, is a global public health epidemic and an increasing concern in Military Health,” says David Okonkwo, MD, Ph,D,, Professor of Neurosurgery at the University of Pittsburgh and Director, Neurotrauma Clinical Trials Center. “There is an urgent need for new innovative technologies that bring objective diagnostic data for TBI. This investment in Neuro Kinetics can accelerate the development and commercialization of this novel technology and take the lead in diagnostics across multiple dimensions of brain health.”
Neuro Kinetics is the leader in providing eye-tracking platforms delivering the most precise and data-rich eye-tracking diagnostic solution in the global market to date. With over 90 variables and 14 FDA cleared tests, Neuro Kinetics solutions includes its critical assets, I-PAS™ and I-Portal™. These foundational platforms help clinicians identify more than 200 diseases and medical conditions early, accurately, and cost-effectively. I-Portal’s non-invasive Science to See™ is enabling Neuro Kinetics to expand its presence in the vestibular market into new areas and applications in traumatic brain injury, concussion, ophthalmology, and neurology.
“We look forward to the next phase of the company’s growth and development and are very excited to be merging with Neurolign,” said Howison Schroeder, President and Chief Executive Officer of Neuro Kinetics. Schroeder added, “The opportunities created by this transaction provides us with the support we need to further advance our planned developments for the assessment of additional neurological diseases.”
About Neurolign Technologies Inc.
Neurolign Technologies is dedicated to creating a quantum shift in the diagnosis and treatment of neurodegenerative disease. Through the unique combination of high precision medical devices as well as specialty formulations and drug delivery technologies, Neurolign is creating a revolutionary approach to the assessment and treatment of brain injury and disease. Whether you are a patient or a medical professional, our world-class diagnostics and novel therapeutics can support the pursuit of optimal brain health. Our portfolio and services offer an evidence-based, holistic ability to deliver more accurate and timelier diagnostic and treatment options. Additional information on Neurolign is available at www.neurolign.com.
About Neuro Kinetics Inc.
Neuro Kinetics, Inc. is the leader in clinical eye-tracking and non-invasive neuro-functional diagnostics and monitoring, offering technology that identifies abnormal eye responses connected to more than 200 diseases and medical conditions. With over 30 years of experience and more than 150 installations, Neuro Kinetics’ FDA-cleared I-Portal® devices are sold to physical therapists, audiologists, ENTs, neuro-chiropractors, neuro-ophthalmologists, and neurologists around the globe. The company’s FDA-cleared diagnostic platforms include the I-PAS™ (I-Portal® Portable Assessment System), I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG, (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training, and support services. Information about Neuro Kinetics can be found at www.neuro-kinetics.com. 
Cautionary Statement Regarding Forward-Looking Information
Certain statements in this document constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or “forward-looking information” under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our expectations regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, and statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs and market penetration and risks or uncertainties. In some cases, you can identify forward-looking statements by terminology such as “appear”, “unlikely”, “target”, “may”, “will”, “should”, “expects”, “plans”, “plans to”, “anticipates”, “believes”, “estimates”, “predicts”, “confident”, “prospects”, “potential”, “continue”, “intends”, “look forward”, “could”, “would”, “projected”, “goals”, “set to”, “seeking” or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Derek Clark, Chief Operating Officer, Neurolign Technologies Inc.Tel: 1-800-503-3804Email: derek.clark@neurolign.com
Source: Neurolign Technologies Inc